<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/84903742398</prism:url><dc:identifier>SCOPUS_ID:84903742398</dc:identifier><eid>2-s2.0-84903742398</eid><prism:doi>10.2478/raon-2014-0016</prism:doi><dc:title>Brain metastases in lung adenocarcinoma: Impact of EGFR mutation status on incidence and survival</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>26</citedby-count><prism:publicationName>Radiology and Oncology</prism:publicationName><dc:publisher>Association of Radiology and Oncology</dc:publisher><source-id>17866</source-id><prism:issn>15813207 13182099</prism:issn><prism:volume>48</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>173</prism:startingPage><prism:endingPage>183</prism:endingPage><prism:pageRange>173-183</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="36574425600"><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36574425600</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><ce:para>Background. The brain represents a frequent progression site in lung adenocarcinoma. This study was designed to analyse the association between the epidermal growth factor receptor (EGFR) mutation status and the frequency of brain metastases (BM) and survival in routine clinical practice. Patients and methods. We retrospectively analysed the medical records of 629 patients with adenocarcinoma in Slovenia who were tested for EGFR mutations in order to analyse the cumulative incidence of BM, the time from the diagnosis to the development of BM (TDBM), the time from BM to death (TTD) and the median survival. Results. Out of 629 patients, 168 (27%) had BM, 90 patients already at the time of diagnosis. Additional 78 patients developed BM after a median interval of 14.3 months; 25.8 months in EGFR positive and 11.8 months in EGFR negative patients, respectively (p = 0.002). EGFR mutations were present in 47 (28%) patients with BM. The curves for cumulative incidence of BM in EGFR positive and negative patients demonstrate a trend for a higher incidence of BM in EGFR mutant patients at diagnosis (19% vs. 13%, p = 0.078), but no difference later during the course of the disease. The patients with BM at diagnosis had a statistically longer TTD (7.3 months) than patients who developed BM later (3.1 months). The TTD in EGFR positive patients with BM at diagnosis was longer than in EGFR negative patients (12.6 vs. 6.8, p = 0.005), while there was no impact of EGFR status on the TTD of patients who developed BM later. Conclusions. Except for a non-significant increase of frequency of BM at diagnosis in EGFR positive patients, EGFR status had no influence upon the cumulative incidence of BM. EGFR positive patients had a longer time to CNS progression. While EGFR positive patients with BM at diagnosis had a longer survival, EGFR status had no influence on TTD in patients who developed BM later during the course of disease.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/84903742398" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=84903742398&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=84903742398&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60004060" href="https://api.elsevier.com/content/affiliation/affiliation_id/60004060"><affilname>Univerza v Mariboru</affilname><affiliation-city>Maribor</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="113671161" href="https://api.elsevier.com/content/affiliation/affiliation_id/113671161"><affilname>University Clinic</affilname><affiliation-city>Golnik</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="36574425600"><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/36574425600</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="2" auid="56031379200"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56031379200</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/><affiliation id="60004060" href="https://api.elsevier.com/content/affiliation/affiliation_id/60004060"/></author><author seq="3" auid="56245036500"><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.T.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnsek</ce:given-name><preferred-name><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnsek</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56245036500</author-url><affiliation id="113671161" href="https://api.elsevier.com/content/affiliation/affiliation_id/113671161"/></author><author seq="4" auid="7003295818"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7003295818</author-url><affiliation id="113671161" href="https://api.elsevier.com/content/affiliation/affiliation_id/113671161"/></author><author seq="5" auid="55883901600"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55883901600</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author><author seq="6" auid="7004393140"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7004393140</author-url><affiliation id="113671161" href="https://api.elsevier.com/content/affiliation/affiliation_id/113671161"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>Brain metastases</author-keyword><author-keyword>EGFR mutations</author-keyword><author-keyword>Lung adenocarcinoma</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2741" abbrev="MEDI">Radiology, Nuclear Medicine and Imaging</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2017-12-10T13:13:01.825Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="01" month="07" timestamp="2019-07-01T12:27:06.000006-04:00" year="2019"/><ait:date-sort day="01" month="01" year="2014"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2015 Elsevier B.V., All rights reserved.</copyright><itemidlist><ce:doi>10.2478/raon-2014-0016</ce:doi><itemid idtype="PUI">373446550</itemid><itemid idtype="CAR-ID">352998404</itemid><itemid idtype="EMBASE">2014447835</itemid><itemid idtype="SCP">84903742398</itemid><itemid idtype="SGR">84903742398</itemid></itemidlist><history><date-created day="08" month="07" year="2014"/></history><dbcollection>EMBASE</dbcollection><dbcollection>Scopusbase</dbcollection></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords><author-keyword xml:lang="eng">Brain metastases</author-keyword><author-keyword xml:lang="eng">EGFR mutations</author-keyword><author-keyword xml:lang="eng">Lung adenocarcinoma</author-keyword></author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Brain metastases in lung adenocarcinoma: Impact of EGFR mutation status on incidence and survival</titletext></citation-title><author-group><author auid="36574425600" seq="1" type="auth"><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name><preferred-name><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname><ce:given-name>Karmen</ce:given-name></preferred-name></author><author auid="56031379200" seq="2" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name></preferred-name></author><affiliation afid="60000966" country="svn" dptid="103095824"><organization>Department of Radiotherapy, Institute of Oncology Ljubljana</organization><address-part>Zaloška 2</address-part><city-group>1000 Ljubljana</city-group><affiliation-id afid="60000966" dptid="103095824"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="56031379200" seq="2" type="auth"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name><preferred-name><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname><ce:given-name>Matjaz</ce:given-name></preferred-name></author><affiliation afid="60004060" country="svn" dptid="113330242"><organization>Faculty of Medicine, University of Maribor</organization><affiliation-id afid="60004060" dptid="113330242"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="56245036500" seq="3" type="auth"><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.T.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnsek</ce:given-name><preferred-name><ce:initials>N.T.</ce:initials><ce:indexed-name>Hitij N.</ce:indexed-name><ce:surname>Hitij</ce:surname><ce:given-name>Nina Turnsek</ce:given-name></preferred-name></author><author auid="7003295818" seq="4" type="auth"><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name><preferred-name><ce:initials>I.</ce:initials><ce:indexed-name>Kern I.</ce:indexed-name><ce:surname>Kern</ce:surname><ce:given-name>Izidor</ce:given-name></preferred-name></author><author auid="7004393140" seq="6" type="auth"><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name><preferred-name><ce:initials>T.</ce:initials><ce:indexed-name>Cufer T.</ce:indexed-name><ce:surname>Cufer</ce:surname><ce:given-name>Tanja</ce:given-name></preferred-name></author><affiliation afid="113671161" country="svn"><organization>University Clinic</organization><city-group>Golnik</city-group><affiliation-id afid="113671161"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="55883901600" seq="5" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Sadikov A.</ce:indexed-name><ce:surname>Sadikov</ce:surname><ce:given-name>Aleksander</ce:given-name></preferred-name></author><affiliation afid="60031106" country="svn"><organization>Faculty of Computer and Information Science, University of Ljubljana</organization><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person><ce:initials>K.</ce:initials><ce:indexed-name>Stanic K.</ce:indexed-name><ce:surname>Stanic</ce:surname></person><affiliation country="svn"><organization>Department of Radiotherapy, Institute of Oncology Ljubljana</organization><address-part>Zaloška 2</address-part><city-group>1000 Ljubljana</city-group><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng"><ce:para>Background. The brain represents a frequent progression site in lung adenocarcinoma. This study was designed to analyse the association between the epidermal growth factor receptor (EGFR) mutation status and the frequency of brain metastases (BM) and survival in routine clinical practice. Patients and methods. We retrospectively analysed the medical records of 629 patients with adenocarcinoma in Slovenia who were tested for EGFR mutations in order to analyse the cumulative incidence of BM, the time from the diagnosis to the development of BM (TDBM), the time from BM to death (TTD) and the median survival. Results. Out of 629 patients, 168 (27%) had BM, 90 patients already at the time of diagnosis. Additional 78 patients developed BM after a median interval of 14.3 months; 25.8 months in EGFR positive and 11.8 months in EGFR negative patients, respectively (p = 0.002). EGFR mutations were present in 47 (28%) patients with BM. The curves for cumulative incidence of BM in EGFR positive and negative patients demonstrate a trend for a higher incidence of BM in EGFR mutant patients at diagnosis (19% vs. 13%, p = 0.078), but no difference later during the course of the disease. The patients with BM at diagnosis had a statistically longer TTD (7.3 months) than patients who developed BM later (3.1 months). The TTD in EGFR positive patients with BM at diagnosis was longer than in EGFR negative patients (12.6 vs. 6.8, p = 0.005), while there was no impact of EGFR status on the TTD of patients who developed BM later. Conclusions. Except for a non-significant increase of frequency of BM at diagnosis in EGFR positive patients, EGFR status had no influence upon the cumulative incidence of BM. EGFR positive patients had a longer time to CNS progression. While EGFR positive patients with BM at diagnosis had a longer survival, EGFR status had no influence on TTD in patients who developed BM later during the course of disease.</ce:para></abstract></abstracts><source country="deu" srcid="17866" type="j"><sourcetitle>Radiology and Oncology</sourcetitle><sourcetitle-abbrev>Radiol. Oncol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Radiology and Oncology</translated-sourcetitle><issn type="electronic">15813207</issn><issn type="print">13182099</issn><codencode>RONCE</codencode><volisspag><voliss issue="2" volume="48"/><pagerange first="173" last="183"/></volisspag><publicationyear first="2014"/><publicationdate><year>2014</year><date-text>June 2014</date-text></publicationdate><website><ce:e-address type="email">http://www.degruyter.com/view/j/raon</ce:e-address></website><publisher><publishername>Association of Radiology and Oncology</publishername></publisher></source><enhancement><classificationgroup><classifications type="EMCLASS"><classification> <classification-code>14</classification-code> <classification-description>Radiology</classification-description> </classification><classification> <classification-code>15</classification-code> <classification-description>Chest Diseases, Thoracic Surgery and Tuberculosis</classification-description> </classification><classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification><classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification><classification> <classification-code>8</classification-code> <classification-description>Neurology and Neurosurgery</classification-description> </classification></classifications><classifications type="ASJC"><classification>2730</classification><classification>2741</classification></classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications></classificationgroup><chemicalgroup><chemicals source="esbd"><chemical><chemical-name>epidermal growth factor receptor</chemical-name><cas-registry-number>79079-06-4</cas-registry-number></chemical></chemicals></chemicalgroup></enhancement></head><tail><bibliography refcount="53"><reference id="1"><ref-info><ref-title><ref-titletext>Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">3843102736</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Bajard A.</ce:indexed-name><ce:surname>Bajard</ce:surname></author><author seq="2"><ce:initials>V.</ce:initials><ce:indexed-name>Westeel V.</ce:indexed-name><ce:surname>Westeel</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Dubiez A.</ce:indexed-name><ce:surname>Dubiez</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Jacoulet P.</ce:indexed-name><ce:surname>Jacoulet</ce:surname></author><author seq="5"><ce:initials>D.</ce:initials><ce:indexed-name>Pernet D.</ce:indexed-name><ce:surname>Pernet</ce:surname></author><author seq="6"><ce:initials>J.C.</ce:initials><ce:indexed-name>Dalphin J.C.</ce:indexed-name><ce:surname>Dalphin</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="45"/><pagerange first="317" last="323"/></ref-volisspag></ref-info><ref-fulltext>Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC, et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004; 45: 317-23.</ref-fulltext></reference><reference id="2"><ref-info><ref-title><ref-titletext>Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0024271627</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.B.</ce:initials><ce:indexed-name>Sorensen J.B.</ce:indexed-name><ce:surname>Sørensen</ce:surname></author><author seq="2"><ce:initials>H.H.</ce:initials><ce:indexed-name>Hansen H.H.</ce:indexed-name><ce:surname>Hansen</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Hansen M.</ce:indexed-name><ce:surname>Hansen</ce:surname></author><author seq="4"><ce:initials>P.</ce:initials><ce:indexed-name>Dombernowsky P.</ce:indexed-name><ce:surname>Dombernowsky</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="1988"/><ref-volisspag><voliss volume="6"/><pagerange first="1474" last="1480"/></ref-volisspag></ref-info><ref-fulltext>Sørensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988; 6: 1474-80.</ref-fulltext></reference><reference id="3"><ref-info><ref-title><ref-titletext>EGFR mutation status in brain metastases of non-small cell lung carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84871752103</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.</ce:initials><ce:indexed-name>Burel-Vandenbos F.</ce:indexed-name><ce:surname>Burel-Vandenbos</ce:surname></author><author seq="2"><ce:initials>D.</ce:initials><ce:indexed-name>Ambrosetti D.</ce:indexed-name><ce:surname>Ambrosetti</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Coutts M.</ce:indexed-name><ce:surname>Coutts</ce:surname></author><author seq="4"><ce:initials>F.</ce:initials><ce:indexed-name>Pedeutour F.</ce:indexed-name><ce:surname>Pedeutour</ce:surname></author></ref-authors><ref-sourcetitle>J Neurooncol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="111"/><pagerange first="1" last="10"/></ref-volisspag></ref-info><ref-fulltext>Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol 2013; 111: 1-10.</ref-fulltext></reference><reference id="4"><ref-info><ref-title><ref-titletext>Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84881236515</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Ali A.</ce:indexed-name><ce:surname>Ali</ce:surname></author><author seq="2"><ce:initials>J.R.</ce:initials><ce:indexed-name>Goffin J.R.</ce:indexed-name><ce:surname>Goffin</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Arnold A.</ce:indexed-name><ce:surname>Arnold</ce:surname></author><author seq="4"><ce:initials>P.M.</ce:initials><ce:indexed-name>Ellis P.M.</ce:indexed-name><ce:surname>Ellis</ce:surname></author></ref-authors><ref-sourcetitle>Curr Oncol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="20"/><pagerange first="300" last="306"/></ref-volisspag></ref-info><ref-fulltext>Ali A, Goffin JR, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 2013; 20: 300-6.</ref-fulltext></reference><reference id="5"><ref-info><ref-title><ref-titletext>CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84877109191</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.A.</ce:initials><ce:indexed-name>Berger L.A.</ce:indexed-name><ce:surname>Berger</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Riesenberg H.</ce:indexed-name><ce:surname>Riesenberg</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Bokemeyer C.</ce:indexed-name><ce:surname>Bokemeyer</ce:surname></author><author seq="4"><ce:initials>D.</ce:initials><ce:indexed-name>Atanackovic D.</ce:indexed-name><ce:surname>Atanackovic</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="80"/><pagerange first="242" last="248"/></ref-volisspag></ref-info><ref-fulltext>Berger LA, Riesenberg H, Bokemeyer C, Atanackovic D. CNS metastases in non-small-cell lung cancer: Current role of EGFR-TKI therapy and future perspectives. Lung Cancer 2013; 80: 242-8.</ref-fulltext></reference><reference id="6"><ref-info><ref-title><ref-titletext>Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84875432452</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>M.</ce:initials><ce:indexed-name>Linnert M.</ce:indexed-name><ce:surname>Linnert</ce:surname></author><author seq="2"><ce:initials>H.K.</ce:initials><ce:indexed-name>Iversen H.K.</ce:indexed-name><ce:surname>Iversen</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Gehl J.</ce:indexed-name><ce:surname>Gehl</ce:surname></author></ref-authors><ref-sourcetitle>Radiol Oncol</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="46"/><pagerange first="271" last="278"/></ref-volisspag></ref-info><ref-fulltext>Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8.</ref-fulltext></reference><reference id="7"><ref-info><ref-title><ref-titletext>The revised TNM staging system for lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">65549138158</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Rami-Porta R.</ce:indexed-name><ce:surname>Rami-Porta</ce:surname></author><author seq="2"><ce:initials>J.J.</ce:initials><ce:indexed-name>Crowley J.J.</ce:indexed-name><ce:surname>Crowley</ce:surname></author><author seq="3"><ce:initials>P.</ce:initials><ce:indexed-name>Goldstraw P.</ce:indexed-name><ce:surname>Goldstraw</ce:surname></author></ref-authors><ref-sourcetitle>Ann Thorac Cardiovasc Surg</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="15"/><pagerange first="4" last="9"/></ref-volisspag></ref-info><ref-fulltext>Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15: 4-9.</ref-fulltext></reference><reference id="8"><ref-info><ref-title><ref-titletext>Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">63049088734</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.-Y.</ce:initials><ce:indexed-name>Wang S.-Y.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="2"><ce:initials>X.</ce:initials><ce:indexed-name>Ye X.</ce:indexed-name><ce:surname>Ye</ce:surname></author><author seq="3"><ce:initials>W.</ce:initials><ce:indexed-name>Ou W.</ce:indexed-name><ce:surname>Ou</ce:surname></author><author seq="4"><ce:initials>Y.-B.</ce:initials><ce:indexed-name>Lin Y.-B.</ce:indexed-name><ce:surname>Lin</ce:surname></author><author seq="5"><ce:initials>B.-B.</ce:initials><ce:indexed-name>Zhang B.-B.</ce:indexed-name><ce:surname>Zhang</ce:surname></author><author seq="6"><ce:initials>H.</ce:initials><ce:indexed-name>Yang H.</ce:indexed-name><ce:surname>Yang</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="64"/><pagerange first="238" last="243"/></ref-volisspag></ref-info><ref-fulltext>Wang S-Y, Ye X, Ou W, Lin Y-B, Zhang B-B, Yang H. Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer 2009; 64: 238-43.</ref-fulltext></reference><reference id="9"><ref-info><ref-title><ref-titletext>Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0035281920</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.J.</ce:initials><ce:indexed-name>Robnett T.J.</ce:indexed-name><ce:surname>Robnett</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Machtay M.</ce:indexed-name><ce:surname>Machtay</ce:surname></author><author seq="3"><ce:initials>J.P.</ce:initials><ce:indexed-name>Stevenson J.P.</ce:indexed-name><ce:surname>Stevenson</ce:surname></author><author seq="4"><ce:initials>K.M.</ce:initials><ce:indexed-name>Algazy K.M.</ce:indexed-name><ce:surname>Algazy</ce:surname></author><author seq="5"><ce:initials>S.M.</ce:initials><ce:indexed-name>Hahn S.M.</ce:indexed-name><ce:surname>Hahn</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2001"/><ref-volisspag><voliss volume="19"/><pagerange first="1344" last="1349"/></ref-volisspag></ref-info><ref-fulltext>Robnett TJ, Machtay M, Stevenson JP, Algazy KM, Hahn SM. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001; 19: 1344-9.</ref-fulltext></reference><reference id="10"><ref-info><ref-title><ref-titletext>High risk of brain metastases in surgically staged III a non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">20144368113</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.J.</ce:initials><ce:indexed-name>Mamon H.J.</ce:indexed-name><ce:surname>Mamon</ce:surname></author><author seq="2"><ce:initials>B.Y.</ce:initials><ce:indexed-name>Yeap B.Y.</ce:indexed-name><ce:surname>Yeap</ce:surname></author><author seq="3"><ce:initials>P.A.</ce:initials><ce:indexed-name>Janne P.A.</ce:indexed-name><ce:surname>Jänne</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Reblando J.</ce:indexed-name><ce:surname>Reblando</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Shrager S.</ce:indexed-name><ce:surname>Shrager</ce:surname></author><author seq="6"><ce:initials>M.T.</ce:initials><ce:indexed-name>Jaklitsch M.T.</ce:indexed-name><ce:surname>Jaklitsch</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="23"/><pagerange first="1530" last="1537"/></ref-volisspag></ref-info><ref-fulltext>Mamon HJ, Yeap BY, Jänne PA, Reblando J, Shrager S, Jaklitsch MT, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005; 23: 1530-7.</ref-fulltext></reference><reference id="11"><ref-info><ref-title><ref-titletext>Brain metastases in lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">1642569561</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:surname>Smrdel</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Zwitter M.</ce:indexed-name><ce:surname>Zwitter</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Kovac V.</ce:indexed-name><ce:surname>Kovač</ce:surname></author></ref-authors><ref-sourcetitle>Impact of Prognostic Factors on Patient Survival. Radiol Oncol</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="37"/><pagerange first="213" last="216"/></ref-volisspag></ref-info><ref-fulltext>Smrdel U, Zwitter M, Kovač V. Brain metastases in lung cancer. Impact of prognostic factors on patient survival. Radiol Oncol 2003; 37: 213-6.</ref-fulltext></reference><reference id="12"><ref-info><ref-title><ref-titletext>Time from treatment to subsequent diagnosis of brain metastases in stage III nonsmall- cell lung cancer: A retrospective review by the southwest oncology group</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">19444370034</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>L.E.</ce:initials><ce:indexed-name>Gaspar L.E.</ce:indexed-name><ce:surname>Gaspar</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Chansky K.</ce:indexed-name><ce:surname>Chansky</ce:surname></author><author seq="3"><ce:initials>K.S.</ce:initials><ce:indexed-name>Albain K.S.</ce:indexed-name><ce:surname>Albain</ce:surname></author><author seq="4"><ce:initials>E.</ce:initials><ce:indexed-name>Vallieres E.</ce:indexed-name><ce:surname>Vallieres</ce:surname></author><author seq="5"><ce:initials>V.</ce:initials><ce:indexed-name>Rusch V.</ce:indexed-name><ce:surname>Rusch</ce:surname></author><author seq="6"><ce:initials>J.J.</ce:initials><ce:indexed-name>Crowley J.J.</ce:indexed-name><ce:surname>Crowley</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="23"/><pagerange first="2955" last="2961"/></ref-volisspag></ref-info><ref-fulltext>Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III nonsmall- cell lung cancer: A retrospective review by the Southwest Oncology Group. J Clin Oncol 2005; 23: 2955-61.</ref-fulltext></reference><reference id="13"><ref-info><ref-title><ref-titletext>Brain metastases in locally advanced non small cell lung carcinoma after multimodality treatment: Risk factors analysis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0036682258</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.L.</ce:initials><ce:indexed-name>Ceresoli G.L.</ce:indexed-name><ce:surname>Ceresoli</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Reni M.</ce:indexed-name><ce:surname>Reni</ce:surname></author><author seq="3"><ce:initials>G.</ce:initials><ce:indexed-name>Chiesa G.</ce:indexed-name><ce:surname>Chiesa</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Carretta A.</ce:indexed-name><ce:surname>Carretta</ce:surname></author><author seq="5"><ce:initials>S.</ce:initials><ce:indexed-name>Schipani S.</ce:indexed-name><ce:surname>Schipani</ce:surname></author><author seq="6"><ce:initials>P.</ce:initials><ce:indexed-name>Passoni P.</ce:indexed-name><ce:surname>Passoni</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer</ref-sourcetitle><ref-publicationyear first="2002"/><ref-volisspag><voliss volume="95"/><pagerange first="605" last="612"/></ref-volisspag></ref-info><ref-fulltext>Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, Passoni P, et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 2002; 95: 605-12.</ref-fulltext></reference><reference id="14"><ref-info><ref-title><ref-titletext>Frequent EGFR mutations in brain metastases of lung adenocarcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33747500939</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Matsumoto S.</ce:indexed-name><ce:surname>Matsumoto</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Takahashi K.</ce:indexed-name><ce:surname>Takahashi</ce:surname></author><author seq="3"><ce:initials>R.</ce:initials><ce:indexed-name>Iwakawa R.</ce:indexed-name><ce:surname>Iwakawa</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Matsuno Y.</ce:indexed-name><ce:surname>Matsuno</ce:surname></author><author seq="5"><ce:initials>Y.</ce:initials><ce:indexed-name>Nakanishi Y.</ce:indexed-name><ce:surname>Nakanishi</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Kohno T.</ce:indexed-name><ce:surname>Kohno</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Int J Cancer</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="119"/><pagerange first="1491" last="1494"/></ref-volisspag></ref-info><ref-fulltext>Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer 2006; 119: 1491-4.</ref-fulltext></reference><reference id="15"><ref-info><ref-title><ref-titletext>Clinical significance of EGFR on progression of brain meta</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84903733256</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Fujiwara S.</ce:indexed-name><ce:surname>Fujiwara</ce:surname></author><author seq="2"><ce:initials>H.</ce:initials><ce:indexed-name>Murakami H.</ce:indexed-name><ce:surname>Murakami</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Shukuya T.</ce:indexed-name><ce:surname>Shukuya</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Ono A.</ce:indexed-name><ce:surname>Ono</ce:surname></author><author seq="5"><ce:initials>A.</ce:initials><ce:indexed-name>Tsuye A.</ce:indexed-name><ce:surname>Tsuye</ce:surname></author><author seq="6"><ce:initials>Y.</ce:initials><ce:indexed-name>Nakamura Y.</ce:indexed-name><ce:surname>Nakamura</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Thorac Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss issue="SUPPL. 2" volume="6"/><pagerange first="1214"/></ref-volisspag></ref-info><ref-fulltext>Fujiwara S, Murakami H, Shukuya T, Ono A, Tsuye A, Nakamura Y, et al. Clinical significance of EGFR on progression of brain meta. J Thorac Oncol 2011; 6(Suppl 2): 1214.</ref-fulltext></reference><reference id="16"><ref-info><ref-title><ref-titletext>Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84861748432</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Sekine A.</ce:indexed-name><ce:surname>Sekine</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Kato T.</ce:indexed-name><ce:surname>Kato</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Hagiwara E.</ce:indexed-name><ce:surname>Hagiwara</ce:surname></author><author seq="4"><ce:initials>T.</ce:initials><ce:indexed-name>Shinohara T.</ce:indexed-name><ce:surname>Shinohara</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Komagata T.</ce:indexed-name><ce:surname>Komagata</ce:surname></author><author seq="6"><ce:initials>T.</ce:initials><ce:indexed-name>Iwasawa T.</ce:indexed-name><ce:surname>Iwasawa</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="77"/><pagerange first="64" last="69"/></ref-volisspag></ref-info><ref-fulltext>Sekine A, Kato T, Hagiwara E, Shinohara T, Komagata T, Iwasawa T, et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 2012; 77: 64-9.</ref-fulltext></reference><reference id="17"><ref-info><ref-title><ref-titletext>East meets west:ethnic differences in epidemiology and clinical behaviours of lung cancer between east asian and caucasians</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79958178777</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.C.D.</ce:initials><ce:indexed-name>Zhou W.C.D.</ce:indexed-name><ce:surname>Zhou</ce:surname></author></ref-authors><ref-sourcetitle>Chin J Cancer</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="30"/><pagerange first="287" last="292"/></ref-volisspag></ref-info><ref-fulltext>Zhou Wei CD. East meets West:ethnic differences in epidemiology and clinical behaviours of lung cancer between East Asian and Caucasians. Chin J Cancer 2011; 30: 287-92.</ref-fulltext></reference><reference id="18"><ref-info><ref-title><ref-titletext>Egfr exon mutation distribution and outcome in non-small-cell lung cancer: A portuguese retrospective study</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">85027933944</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>F.S.</ce:initials><ce:indexed-name>Pires F.S.</ce:indexed-name><ce:surname>Pires</ce:surname></author><author seq="2"><ce:initials>D.S.</ce:initials><ce:indexed-name>Marques D.S.</ce:indexed-name><ce:surname>Marques</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Oliveira J.</ce:indexed-name><ce:surname>Oliveira</ce:surname></author><author seq="4"><ce:initials>A.</ce:initials><ce:indexed-name>Rodrigues A.</ce:indexed-name><ce:surname>Rodrigues</ce:surname></author><author seq="5"><ce:initials>M.</ce:initials><ce:indexed-name>Soares M.</ce:indexed-name><ce:surname>Soares</ce:surname></author><author seq="6"><ce:initials>R.A.</ce:initials><ce:indexed-name>De Mello R.A.</ce:indexed-name><ce:surname>De Mello</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Tumor Biol</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="33"/><pagerange first="2061" last="2068"/></ref-volisspag></ref-info><ref-fulltext>de Mello, RA, Pires FS, Marques DS, Oliveira J, Rodrigues A, Soares M, et al. EGFR exon mutation distribution and outcome in non-small-cell lung cancer: A Portuguese retrospective study. Tumor Biol 2012; 33: 2061-8.</ref-fulltext></reference><reference id="19"><ref-info><ref-title><ref-titletext>The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84857088535</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Z.</ce:initials><ce:indexed-name>Li Z.</ce:indexed-name><ce:surname>Li</ce:surname></author><author seq="2"><ce:initials>J.</ce:initials><ce:indexed-name>Lu J.</ce:indexed-name><ce:surname>Lu</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Zhao Y.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><author seq="4"><ce:initials>H.</ce:initials><ce:indexed-name>Guo H.</ce:indexed-name><ce:surname>Guo</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="29"/><pages>e18065</pages></ref-volisspag></ref-info><ref-fulltext>Li Z, Lu J, Zhao Y, Guo H. The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. J Clin Oncol 2011; 29: e18065.</ref-fulltext></reference><reference id="20"><ref-info><ref-title><ref-titletext>Characteristics of metastatic brain tumor in patients with lung adenocarcinoma with mutation of epidermal growth factor receptor gene</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84903747901</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Sekine A.</ce:indexed-name><ce:surname>Sekine</ce:surname></author></ref-authors><ref-sourcetitle>Am J Respir Crit Care Med</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="181"/><pages>A5147</pages></ref-volisspag></ref-info><ref-fulltext>Sekine A. Characteristics of metastatic brain tumor in patients with lung adenocarcinoma with mutation of epidermal growth factor receptor gene. Am J Respir Crit Care Med 2010; 181: A5147.</ref-fulltext></reference><reference id="21"><ref-info><ref-title><ref-titletext>Activating mutations within the EGFR kinase domain: A molecular predictor of disease-free survival in resected pulmonary adenocarcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">70349758654</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.J.</ce:initials><ce:indexed-name>Lee Y.J.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>I.K.</ce:initials><ce:indexed-name>Park I.K.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="3"><ce:initials>M.-S.</ce:initials><ce:indexed-name>Park M.-S.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="4"><ce:initials>H.J.</ce:initials><ce:indexed-name>Choi H.J.</ce:indexed-name><ce:surname>Choi</ce:surname></author><author seq="5"><ce:initials>B.C.</ce:initials><ce:indexed-name>Cho B.C.</ce:indexed-name><ce:surname>Cho</ce:surname></author><author seq="6"><ce:initials>K.Y.</ce:initials><ce:indexed-name>Chung K.Y.</ce:indexed-name><ce:surname>Chung</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Cancer Res Clin Oncol</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="135"/><pagerange first="1647" last="1654"/></ref-volisspag></ref-info><ref-fulltext>Lee YJ, Park IK, Park M-S, Choi HJ, Cho BC, Chung KY, et al. Activating mutations within the EGFR kinase domain: A molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol 2009; 135: 1647-54.</ref-fulltext></reference><reference id="22"><ref-info><ref-title><ref-titletext>Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">79952268212</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>R.</ce:initials><ce:indexed-name>Porta R.</ce:indexed-name><ce:surname>Porta</ce:surname></author><author seq="2"><ce:initials>J.M.</ce:initials><ce:indexed-name>Sanchez-Torres J.M.</ce:indexed-name><ce:surname>Sánchez-Torres</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Paz-Ares L.</ce:indexed-name><ce:surname>Paz-Ares</ce:surname></author><author seq="4"><ce:initials>B.</ce:initials><ce:indexed-name>Massuti B.</ce:indexed-name><ce:surname>Massutí</ce:surname></author><author seq="5"><ce:initials>N.</ce:initials><ce:indexed-name>Reguart N.</ce:indexed-name><ce:surname>Reguart</ce:surname></author><author seq="6"><ce:initials>C.</ce:initials><ce:indexed-name>Mayo C.</ce:indexed-name><ce:surname>Mayo</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Eur Respir J</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="37"/><pagerange first="624" last="631"/></ref-volisspag></ref-info><ref-fulltext>Porta R, Sánchez-Torres JM, Paz-Ares L, Massutí B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: The importance of EGFR mutation. Eur Respir J 2011; 37: 624-31.</ref-fulltext></reference><reference id="23"><ref-info><ref-title><ref-titletext>Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84864674138</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.I.</ce:initials><ce:indexed-name>Na I.I.</ce:indexed-name><ce:surname>Na</ce:surname></author><author seq="2"><ce:initials>J.H.</ce:initials><ce:indexed-name>Park J.H.</ce:indexed-name><ce:surname>Park</ce:surname></author><author seq="3"><ce:initials>D.H.</ce:initials><ce:indexed-name>Choe D.H.</ce:indexed-name><ce:surname>Choe</ce:surname></author><author seq="4"><ce:initials>J.K.</ce:initials><ce:indexed-name>Lee J.K.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="5"><ce:initials>J.S.</ce:initials><ce:indexed-name>Koh J.S.</ce:indexed-name><ce:surname>Koh</ce:surname></author></ref-authors><ref-sourcetitle>ISRN Oncol 2011</ref-sourcetitle><ref-volisspag><voliss volume="2011"/><pagerange first="265" last="756"/></ref-volisspag></ref-info><ref-fulltext>Na II, Park JH, Choe DH, Lee JK, Koh JS. Association of epidermal growth factor receptor mutations with metastatic presentations in non-small cell lung cancer. ISRN Oncol 2011; 2011: 756-265.</ref-fulltext></reference><reference id="24"><ref-info><ref-title><ref-titletext>Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">55749089552</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.G.</ce:initials><ce:indexed-name>Saad A.G.</ce:indexed-name><ce:surname>Saad</ce:surname></author><author seq="2"><ce:initials>B.Y.</ce:initials><ce:indexed-name>Yeap B.Y.</ce:indexed-name><ce:surname>Yeap</ce:surname></author><author seq="3"><ce:initials>F.B.J.M.</ce:initials><ce:indexed-name>Thunnissen F.B.J.M.</ce:indexed-name><ce:surname>Thunnissen</ce:surname></author><author seq="4"><ce:initials>G.S.</ce:initials><ce:indexed-name>Pinkus G.S.</ce:indexed-name><ce:surname>Pinkus</ce:surname></author><author seq="5"><ce:initials>J.L.</ce:initials><ce:indexed-name>Pinkus J.L.</ce:indexed-name><ce:surname>Pinkus</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Loda M.</ce:indexed-name><ce:surname>Loda</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="113"/><pagerange first="2129" last="2138"/></ref-volisspag></ref-info><ref-fulltext>Saad AG, Yeap BY, Thunnissen FBJM, Pinkus GS, Pinkus JL, Loda M, et al. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. Cancer 2008; 113: 2129-38.</ref-fulltext></reference><reference id="25"><ref-info><refd-itemidlist><itemid idtype="SGR">84903736261</itemid></refd-itemidlist><ref-sourcetitle>Epidemiology and Cancer Registry</ref-sourcetitle><ref-publicationyear first="2010"/><ref-text>Cancer in Slovenia, Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2013</ref-text></ref-info><ref-fulltext>Cancer in Slovenia 2010. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2013.</ref-fulltext></reference><reference id="26"><ref-info><ref-title><ref-titletext>Egfr mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650127780</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.F.</ce:initials><ce:indexed-name>Eichler A.F.</ce:indexed-name><ce:surname>Eichler</ce:surname></author><author seq="2"><ce:initials>K.T.</ce:initials><ce:indexed-name>Kahle K.T.</ce:indexed-name><ce:surname>Kahle</ce:surname></author><author seq="3"><ce:initials>D.L.</ce:initials><ce:indexed-name>Wang D.L.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>V.A.</ce:initials><ce:indexed-name>Joshi V.A.</ce:indexed-name><ce:surname>Joshi</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Willers H.</ce:indexed-name><ce:surname>Willers</ce:surname></author><author seq="6"><ce:initials>J.A.</ce:initials><ce:indexed-name>Engelman J.A.</ce:indexed-name><ce:surname>Engelman</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neuro Oncol</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="12"/><pagerange first="1193" last="1199"/></ref-volisspag></ref-info><ref-fulltext>Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010; 12: 1193-9.</ref-fulltext></reference><reference id="27"><ref-info><ref-title><ref-titletext>Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">78650390328</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Heon S.</ce:indexed-name><ce:surname>Heon</ce:surname></author><author seq="2"><ce:initials>B.Y.</ce:initials><ce:indexed-name>Yeap B.Y.</ce:indexed-name><ce:surname>Yeap</ce:surname></author><author seq="3"><ce:initials>G.J.</ce:initials><ce:indexed-name>Britt G.J.</ce:indexed-name><ce:surname>Britt</ce:surname></author><author seq="4"><ce:initials>D.B.</ce:initials><ce:indexed-name>Costa D.B.</ce:indexed-name><ce:surname>Costa</ce:surname></author><author seq="5"><ce:initials>M.S.</ce:initials><ce:indexed-name>Rabin M.S.</ce:indexed-name><ce:surname>Rabin</ce:surname></author><author seq="6"><ce:initials>D.M.</ce:initials><ce:indexed-name>Jackman D.M.</ce:indexed-name><ce:surname>Jackman</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="16"/><pagerange first="5873" last="5882"/></ref-volisspag></ref-info><ref-fulltext>Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16: 5873-82.</ref-fulltext></reference><reference id="28"><ref-info><ref-title><ref-titletext>EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84867897974</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.L.</ce:initials><ce:indexed-name>Lee H.L.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>T.S.</ce:initials><ce:indexed-name>Chung T.S.</ce:indexed-name><ce:surname>Chung</ce:surname></author><author seq="3"><ce:initials>L.L.</ce:initials><ce:indexed-name>Ting L.L.</ce:indexed-name><ce:surname>Ting</ce:surname></author><author seq="4"><ce:initials>J.T.</ce:initials><ce:indexed-name>Tsai J.T.</ce:indexed-name><ce:surname>Tsai</ce:surname></author><author seq="5"><ce:initials>S.W.</ce:initials><ce:indexed-name>Chen S.W.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="6"><ce:initials>J.F.</ce:initials><ce:indexed-name>Chiou J.F.</ce:indexed-name><ce:surname>Chiou</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Radiat Oncol</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="7"/><pagerange first="181"/></ref-volisspag></ref-info><ref-fulltext>Lee HL, Chung TS, Ting LL, Tsai JT, Chen SW, Chiou JF, et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 2012; 7: 181.</ref-fulltext></reference><reference id="29"><ref-info><ref-title><ref-titletext>Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84881667804</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.H.</ce:initials><ce:indexed-name>Hsiao S.H.</ce:indexed-name><ce:surname>Hsiao</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="81"/><pagerange first="455" last="461"/></ref-volisspag></ref-info><ref-fulltext>Hsiao SH. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer 2013; 81: 455-61.</ref-fulltext></reference><reference id="30"><ref-info><ref-title><ref-titletext>Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84903690869</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Komatsu T.</ce:indexed-name><ce:surname>Komatsu</ce:surname></author><author seq="2"><ce:initials>E.</ce:initials><ce:indexed-name>Kunieda E.</ce:indexed-name><ce:surname>Kunieda</ce:surname></author><author seq="3"><ce:initials>Y.</ce:initials><ce:indexed-name>Oizumi Y.</ce:indexed-name><ce:surname>Oizumi</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Tamai Y.</ce:indexed-name><ce:surname>Tamai</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Akiba T.</ce:indexed-name><ce:surname>Akiba</ce:surname></author></ref-authors><ref-sourcetitle>Mol Clin Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="1"/><pagerange first="692" last="698"/></ref-volisspag></ref-info><ref-fulltext>Komatsu T, Kunieda E, Oizumi Y, Tamai Y, Akiba T. Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy. Mol Clin Oncol 2011; 1: 692-8.</ref-fulltext></reference><reference id="31"><ref-info><ref-title><ref-titletext>Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">40749142429</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.-H.</ce:initials><ce:indexed-name>Gow C.-H.</ce:indexed-name><ce:surname>Gow</ce:surname></author><author seq="2"><ce:initials>C.-R.</ce:initials><ce:indexed-name>Chien C.-R.</ce:indexed-name><ce:surname>Chien</ce:surname></author><author seq="3"><ce:initials>Y.-L.</ce:initials><ce:indexed-name>Chang Y.-L.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="4"><ce:initials>Y.-H.</ce:initials><ce:indexed-name>Chiu Y.-H.</ce:indexed-name><ce:surname>Chiu</ce:surname></author><author seq="5"><ce:initials>S.-H.</ce:initials><ce:indexed-name>Kuo S.-H.</ce:indexed-name><ce:surname>Kuo</ce:surname></author><author seq="6"><ce:initials>J.-Y.</ce:initials><ce:indexed-name>Shih J.-Y.</ce:indexed-name><ce:surname>Shih</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="14"/><pagerange first="162" last="168"/></ref-volisspag></ref-info><ref-fulltext>Gow C-H, Chien C-R, Chang Y-L, Chiu Y-H, Kuo S-H, Shih J-Y, et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008; 14: 162-8.</ref-fulltext></reference><reference id="32"><ref-info><ref-title><ref-titletext>Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84857131400</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.L.</ce:initials><ce:indexed-name>Ceresoli G.L.</ce:indexed-name><ce:surname>Ceresoli</ce:surname></author></ref-authors><ref-sourcetitle>Curr Cancer Drug Targets</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="12"/><pagerange first="237" last="246"/></ref-volisspag></ref-info><ref-fulltext>Ceresoli GL. Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. Curr Cancer Drug Targets 2012; 12: 237-46.</ref-fulltext></reference><reference id="33"><ref-info><ref-title><ref-titletext>Non-smallcell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33750339641</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.K.</ce:initials><ce:indexed-name>Das A.K.</ce:indexed-name><ce:surname>Das</ce:surname></author><author seq="2"><ce:initials>M.</ce:initials><ce:indexed-name>Sato M.</ce:indexed-name><ce:surname>Sato</ce:surname></author><author seq="3"><ce:initials>M.D.</ce:initials><ce:indexed-name>Story M.D.</ce:indexed-name><ce:surname>Story</ce:surname></author><author seq="4"><ce:initials>M.</ce:initials><ce:indexed-name>Peyton M.</ce:indexed-name><ce:surname>Peyton</ce:surname></author><author seq="5"><ce:initials>R.</ce:initials><ce:indexed-name>Graves R.</ce:indexed-name><ce:surname>Graves</ce:surname></author><author seq="6"><ce:initials>S.</ce:initials><ce:indexed-name>Redpath S.</ce:indexed-name><ce:surname>Redpath</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Res</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="66"/><pagerange first="9601" last="9608"/></ref-volisspag></ref-info><ref-fulltext>Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, et al. Non-smallcell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006; 66: 9601-8.</ref-fulltext></reference><reference id="34"><ref-info><ref-title><ref-titletext>The epidermal growth factor receptor mediates radioresistance</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0041563993</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>K.</ce:initials><ce:indexed-name>Liang K.</ce:indexed-name><ce:surname>Liang</ce:surname></author><author seq="2"><ce:initials>K.K.</ce:initials><ce:indexed-name>Ang K.K.</ce:indexed-name><ce:surname>Ang</ce:surname></author><author seq="3"><ce:initials>L.</ce:initials><ce:indexed-name>Milas L.</ce:indexed-name><ce:surname>Milas</ce:surname></author><author seq="4"><ce:initials>N.</ce:initials><ce:indexed-name>Hunter N.</ce:indexed-name><ce:surname>Hunter</ce:surname></author><author seq="5"><ce:initials>Z.</ce:initials><ce:indexed-name>Fan Z.</ce:indexed-name><ce:surname>Fan</ce:surname></author></ref-authors><ref-sourcetitle>Int J Radiat Oncol</ref-sourcetitle><ref-publicationyear first="2003"/><ref-volisspag><voliss volume="57"/><pagerange first="246" last="254"/></ref-volisspag></ref-info><ref-fulltext>Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol 2003; 57: 246-54.</ref-fulltext></reference><reference id="35"><ref-info><ref-title><ref-titletext>Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">39749129748</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>T.</ce:initials><ce:indexed-name>Tanaka T.</ce:indexed-name><ce:surname>Tanaka</ce:surname></author><author seq="2"><ce:initials>A.</ce:initials><ce:indexed-name>Munshi A.</ce:indexed-name><ce:surname>Munshi</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Brooks C.</ce:indexed-name><ce:surname>Brooks</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Liu J.</ce:indexed-name><ce:surname>Liu</ce:surname></author><author seq="5"><ce:initials>M.L.</ce:initials><ce:indexed-name>Hobbs M.L.</ce:indexed-name><ce:surname>Hobbs</ce:surname></author><author seq="6"><ce:initials>R.E.</ce:initials><ce:indexed-name>Meyn R.E.</ce:indexed-name><ce:surname>Meyn</ce:surname></author></ref-authors><ref-sourcetitle>Clin Cancer Res</ref-sourcetitle><ref-publicationyear first="2008"/><ref-volisspag><voliss volume="14"/><pagerange first="1266" last="1273"/></ref-volisspag></ref-info><ref-fulltext>Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008; 14: 1266-73.</ref-fulltext></reference><reference id="36"><ref-info><ref-title><ref-titletext>Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non- small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67651102970</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.</ce:initials><ce:indexed-name>Lind J.</ce:indexed-name><ce:surname>Lind</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Lagerwaard F.</ce:indexed-name><ce:surname>Lagerwaard</ce:surname></author><author seq="3"><ce:initials>E.</ce:initials><ce:indexed-name>Smit E.</ce:indexed-name><ce:surname>Smit</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Senan S.</ce:indexed-name><ce:surname>Senan</ce:surname></author></ref-authors><ref-sourcetitle>Int J Radiat Oncol Biol Phys</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="74"/><pagerange first="1391" last="1396"/></ref-volisspag></ref-info><ref-fulltext>Lind J, Lagerwaard F, Smit E, Senan S. Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non- Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2009; 74: 1391-6.</ref-fulltext></reference><reference id="37"><ref-info><ref-title><ref-titletext>Phase ii trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84875720245</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.W.</ce:initials><ce:indexed-name>Welsh J.W.</ce:indexed-name><ce:surname>Welsh</ce:surname></author><author seq="2"><ce:initials>R.</ce:initials><ce:indexed-name>Komaki R.</ce:indexed-name><ce:surname>Komaki</ce:surname></author><author seq="3"><ce:initials>A.</ce:initials><ce:indexed-name>Amini A.</ce:indexed-name><ce:surname>Amini</ce:surname></author><author seq="4"><ce:initials>M.F.</ce:initials><ce:indexed-name>Munsell M.F.</ce:indexed-name><ce:surname>Munsell</ce:surname></author><author seq="5"><ce:initials>W.</ce:initials><ce:indexed-name>Unger W.</ce:indexed-name><ce:surname>Unger</ce:surname></author><author seq="6"><ce:initials>P.K.</ce:initials><ce:indexed-name>Allen P.K.</ce:indexed-name><ce:surname>Allen</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="31"/><pagerange first="895" last="902"/></ref-volisspag></ref-info><ref-fulltext>Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013; 31: 895-902.</ref-fulltext></reference><reference id="38"><ref-info><ref-title><ref-titletext>Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a chinese population</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">67449122414</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Ma S.</ce:indexed-name><ce:surname>Ma</ce:surname></author><author seq="2"><ce:initials>Y.</ce:initials><ce:indexed-name>Xu Y.</ce:indexed-name><ce:surname>Xu</ce:surname></author><author seq="3"><ce:initials>Q.</ce:initials><ce:indexed-name>Deng Q.</ce:indexed-name><ce:surname>Deng</ce:surname></author><author seq="4"><ce:initials>X.</ce:initials><ce:indexed-name>Yu X.</ce:indexed-name><ce:surname>Yu</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="65"/><pagerange first="198" last="203"/></ref-volisspag></ref-info><ref-fulltext>Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 2009; 65: 198-203.</ref-fulltext></reference><reference id="39"><ref-info><ref-title><ref-titletext>Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77957016551</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>I.</ce:initials><ce:indexed-name>Olmez I.</ce:indexed-name><ce:surname>Olmez</ce:surname></author><author seq="2"><ce:initials>B.R.</ce:initials><ce:indexed-name>Donahue B.R.</ce:indexed-name><ce:surname>Donahue</ce:surname></author><author seq="3"><ce:initials>J.S.</ce:initials><ce:indexed-name>Butler J.S.</ce:indexed-name><ce:surname>Butler</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Huang Y.</ce:indexed-name><ce:surname>Huang</ce:surname></author><author seq="5"><ce:initials>P.X.Y.</ce:initials><ce:indexed-name>Rubin P.X.Y.</ce:indexed-name><ce:surname>Rubin</ce:surname></author></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="70"/><pagerange first="174" last="179"/></ref-volisspag></ref-info><ref-fulltext>Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P XY. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung cancer 2010; 70: 174-9.</ref-fulltext></reference><reference id="40"><ref-info><ref-title><ref-titletext>Phase ii study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84885224003</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>H.</ce:initials><ce:indexed-name>Zhuang H.</ce:indexed-name><ce:surname>Zhuang</ce:surname></author><author seq="2"><ce:initials>Z.</ce:initials><ce:indexed-name>Yuan Z.</ce:indexed-name><ce:surname>Yuan</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Wang J.</ce:indexed-name><ce:surname>Wang</ce:surname></author><author seq="4"><ce:initials>L.</ce:initials><ce:indexed-name>Zhao L.</ce:indexed-name><ce:surname>Zhao</ce:surname></author><author seq="5"><ce:initials>Q.</ce:initials><ce:indexed-name>Pang Q.</ce:indexed-name><ce:surname>Pang</ce:surname></author><author seq="6"><ce:initials>P.</ce:initials><ce:indexed-name>Wang P.</ce:indexed-name><ce:surname>Wang</ce:surname></author></ref-authors><ref-sourcetitle>Drug des Devel Ther</ref-sourcetitle><ref-publicationyear first="2013"/><ref-volisspag><voliss volume="7"/><pagerange first="179" last="186"/></ref-volisspag></ref-info><ref-fulltext>Zhuang H, Yuan Z, Wang J, Zhao L, Pang Q, Wang P. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Des Devel Ther 2013; 7: 179- 86.</ref-fulltext></reference><reference id="41"><ref-info><ref-title><ref-titletext>Efficacy of increased-dose erlotinib for central nervous system metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80054730405</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.</ce:initials><ce:indexed-name>Togashi Y.</ce:indexed-name><ce:surname>Togashi</ce:surname></author><author seq="2"><ce:initials>K.</ce:initials><ce:indexed-name>Masago K.</ce:indexed-name><ce:surname>Masago</ce:surname></author><author seq="3"><ce:initials>M.</ce:initials><ce:indexed-name>Fukudo M.</ce:indexed-name><ce:surname>Fukudo</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Tsuchido Y.</ce:indexed-name><ce:surname>Tsuchido</ce:surname></author><author seq="5"><ce:initials>C.</ce:initials><ce:indexed-name>Okuda C.</ce:indexed-name><ce:surname>Okuda</ce:surname></author><author seq="6"><ce:initials>Y.H.</ce:initials><ce:indexed-name>Kim Y.H.</ce:indexed-name><ce:surname>Kim</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Chemother Pharmacol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="68"/><pagerange first="1089" last="1092"/></ref-volisspag></ref-info><ref-fulltext>Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, et al. Efficacy of increased-dose erlotinib for central nervous system metastases in nonsmall cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011; 68: 1089-92.</ref-fulltext></reference><reference id="42"><ref-info><ref-title><ref-titletext>Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84856304068</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Grommes C.</ce:indexed-name><ce:surname>Grommes</ce:surname></author><author seq="2"><ce:initials>G.R.</ce:initials><ce:indexed-name>Oxnard G.R.</ce:indexed-name><ce:surname>Oxnard</ce:surname></author><author seq="3"><ce:initials>M.G.</ce:initials><ce:indexed-name>Kris M.G.</ce:indexed-name><ce:surname>Kris</ce:surname></author><author seq="4"><ce:initials>V.A.</ce:initials><ce:indexed-name>Miller V.A.</ce:indexed-name><ce:surname>Miller</ce:surname></author><author seq="5"><ce:initials>W.</ce:initials><ce:indexed-name>Pao W.</ce:indexed-name><ce:surname>Pao</ce:surname></author><author seq="6"><ce:initials>A.I.</ce:initials><ce:indexed-name>Holodny A.I.</ce:indexed-name><ce:surname>Holodny</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neuro Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="13"/><pagerange first="1364" last="1369"/></ref-volisspag></ref-info><ref-fulltext>Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011; 13: 1364-9.</ref-fulltext></reference><reference id="43"><ref-info><ref-title><ref-titletext>Randomized phase ii study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">83555166254</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.T.</ce:initials><ce:indexed-name>Kim S.T.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="2"><ce:initials>J.E.</ce:initials><ce:indexed-name>Uhm J.E.</ce:indexed-name><ce:surname>Uhm</ce:surname></author><author seq="3"><ce:initials>J.</ce:initials><ce:indexed-name>Lee J.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Sun J.</ce:indexed-name><ce:surname>Sun</ce:surname></author><author seq="5"><ce:initials>I.</ce:initials><ce:indexed-name>Sohn I.</ce:indexed-name><ce:surname>Sohn</ce:surname></author><author seq="6"><ce:initials>S.W.</ce:initials><ce:indexed-name>Kim S.W.</ce:indexed-name><ce:surname>Kim</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Lung Cancer</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="75"/><pagerange first="82" last="88"/></ref-volisspag></ref-info><ref-fulltext>Kim ST, Uhm JE, Lee J, Sun J, Sohn I, Kim SW, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012; 75: 82-8.</ref-fulltext></reference><reference id="44"><ref-info><ref-title><ref-titletext>EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">33744481276</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Shimato S.</ce:indexed-name><ce:surname>Shimato</ce:surname></author><author seq="2"><ce:initials>T.</ce:initials><ce:indexed-name>Mitsudomi T.</ce:indexed-name><ce:surname>Mitsudomi</ce:surname></author><author seq="3"><ce:initials>T.</ce:initials><ce:indexed-name>Kosaka T.</ce:indexed-name><ce:surname>Kosaka</ce:surname></author><author seq="4"><ce:initials>Y.</ce:initials><ce:indexed-name>Yatabe Y.</ce:indexed-name><ce:surname>Yatabe</ce:surname></author><author seq="5"><ce:initials>T.</ce:initials><ce:indexed-name>Wakabayashi T.</ce:indexed-name><ce:surname>Wakabayashi</ce:surname></author><author seq="6"><ce:initials>M.</ce:initials><ce:indexed-name>Mizuno M.</ce:indexed-name><ce:surname>Mizuno</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Neuro Oncol</ref-sourcetitle><ref-publicationyear first="2006"/><ref-volisspag><voliss volume="8"/><pagerange first="137" last="144"/></ref-volisspag></ref-info><ref-fulltext>Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, et al. EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro Oncol 2006; 8: 137-44.</ref-fulltext></reference><reference id="45"><ref-info><ref-title><ref-titletext>Near total regression of diffuse brain metastases in adenocarcinoma of the lung with an EGFR Exon 19 mutation: A case report and review of the literature</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84855314869</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>W.-H.</ce:initials><ce:indexed-name>Tang W.-H.</ce:indexed-name><ce:surname>Tang</ce:surname></author><author seq="2"><ce:initials>J.-H.</ce:initials><ce:indexed-name>Chen J.-H.</ce:indexed-name><ce:surname>Chen</ce:surname></author><author seq="3"><ce:initials>R.-H.</ce:initials><ce:indexed-name>Ye R.-H.</ce:indexed-name><ce:surname>Ye</ce:surname></author><author seq="4"><ce:initials>C.-L.</ce:initials><ce:indexed-name>Ho C.-L.</ce:indexed-name><ce:surname>Ho</ce:surname></author></ref-authors><ref-sourcetitle>Case Rep Oncol</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="4"/><pagerange first="445" last="451"/></ref-volisspag></ref-info><ref-fulltext>Tang W-H, Chen J-H, Ye R-H, Ho C-L. Near Total Regression of Diffuse Brain Metastases in Adenocarcinoma of the Lung with an EGFR Exon 19 Mutation: A Case Report and Review of the Literature. Case Rep Oncol 2011; 4: 445-51.</ref-fulltext></reference><reference id="46"><ref-info><ref-title><ref-titletext>Rates of central nervous system (CNS) metastases in patients with advanced nonsmall cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80053519935</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>S.</ce:initials><ce:indexed-name>Heon S.</ce:indexed-name><ce:surname>Heon</ce:surname></author><author seq="2"><ce:initials>B.Y.</ce:initials><ce:indexed-name>Yeap B.Y.</ce:indexed-name><ce:surname>Yeap</ce:surname></author><author seq="3"><ce:initials>N.I.</ce:initials><ce:indexed-name>Lindeman N.I.</ce:indexed-name><ce:surname>Lindeman</ce:surname></author><author seq="4"><ce:initials>M.S.</ce:initials><ce:indexed-name>Rabin M.S.</ce:indexed-name><ce:surname>Rabin</ce:surname></author><author seq="5"><ce:initials>D.J.</ce:initials><ce:indexed-name>Jackman D.J.</ce:indexed-name><ce:surname>Jackman</ce:surname></author><author seq="6"><ce:initials>B.E.</ce:initials><ce:indexed-name>Johnson B.E.</ce:indexed-name><ce:surname>Johnson</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol 2011</ref-sourcetitle><ref-volisspag><voliss issue="SUPPL. 15" volume="29"/><pages>A7607</pages></ref-volisspag></ref-info><ref-fulltext>Heon S, Yeap BY, Lindeman NI, Rabin MS, Jackman DJ, Johnson BE. Rates of central nervous system (CNS) metastases in patients with advanced nonsmall cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy. J Clin Oncol 2011; 29(Suppl 15): A7607.</ref-fulltext></reference><reference id="47"><ref-info><ref-title><ref-titletext>Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">4143110253</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>G.L.</ce:initials><ce:indexed-name>Ceresoli G.L.</ce:indexed-name><ce:surname>Ceresoli</ce:surname></author><author seq="2"><ce:initials>F.</ce:initials><ce:indexed-name>Cappuzzo F.</ce:indexed-name><ce:surname>Cappuzzo</ce:surname></author><author seq="3"><ce:initials>V.</ce:initials><ce:indexed-name>Gregorc V.</ce:indexed-name><ce:surname>Gregorc</ce:surname></author><author seq="4"><ce:initials>S.</ce:initials><ce:indexed-name>Bartolini S.</ce:indexed-name><ce:surname>Bartolini</ce:surname></author><author seq="5"><ce:initials>L.</ce:initials><ce:indexed-name>Crino L.</ce:indexed-name><ce:surname>Crinò</ce:surname></author><author seq="6"><ce:initials>E.</ce:initials><ce:indexed-name>Villa E.</ce:indexed-name><ce:surname>Villa</ce:surname></author></ref-authors><ref-sourcetitle>Ann Oncol</ref-sourcetitle><ref-publicationyear first="2004"/><ref-volisspag><voliss volume="15"/><pagerange first="1042" last="1047"/></ref-volisspag></ref-info><ref-fulltext>Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann Oncol 2004; 15: 1042-7.</ref-fulltext></reference><reference id="48"><ref-info><ref-title><ref-titletext>Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in korean patients with nonsmall-cell lung cancer</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">77149171468</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>Y.J.</ce:initials><ce:indexed-name>Lee Y.J.</ce:indexed-name><ce:surname>Lee</ce:surname></author><author seq="2"><ce:initials>H.J.</ce:initials><ce:indexed-name>Choi H.J.</ce:indexed-name><ce:surname>Choi</ce:surname></author><author seq="3"><ce:initials>S.K.</ce:initials><ce:indexed-name>Kim S.K.</ce:indexed-name><ce:surname>Kim</ce:surname></author><author seq="4"><ce:initials>J.</ce:initials><ce:indexed-name>Chang J.</ce:indexed-name><ce:surname>Chang</ce:surname></author><author seq="5"><ce:initials>J.W.</ce:initials><ce:indexed-name>Moon J.W.</ce:indexed-name><ce:surname>Moon</ce:surname></author><author seq="6"><ce:initials>I.K.</ce:initials><ce:indexed-name>Park I.K.</ce:indexed-name><ce:surname>Park</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer</ref-sourcetitle><ref-publicationyear first="2010"/><ref-volisspag><voliss volume="116"/><pagerange first="1336" last="1343"/></ref-volisspag></ref-info><ref-fulltext>Lee YJ, Choi HJ, Kim SK, Chang J, Moon JW, Park IK, et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. Cancer 2010; 116: 1336-43.</ref-fulltext></reference><reference id="49"><ref-info><ref-title><ref-titletext>Prophylactic cranial irradiation in locally advanced non small cell lung cancer after multimodality treatment: Long term follow up and investigation of late neuropsychological effects</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">0032829751</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>B.M.</ce:initials><ce:indexed-name>Stuschke B.M.</ce:indexed-name><ce:surname>Stuschke</ce:surname></author><author seq="2"><ce:initials>W.</ce:initials><ce:indexed-name>Eberhardt W.</ce:indexed-name><ce:surname>Eberhardt</ce:surname></author><author seq="3"><ce:initials>C.</ce:initials><ce:indexed-name>Po C.</ce:indexed-name><ce:surname>Po</ce:surname></author><author seq="4"><ce:initials>G.</ce:initials><ce:indexed-name>Stamatis G.</ce:indexed-name><ce:surname>Stamatis</ce:surname></author><author seq="5"><ce:initials>H.</ce:initials><ce:indexed-name>Wilke H.</ce:indexed-name><ce:surname>Wilke</ce:surname></author><author seq="6"><ce:initials>G.</ce:initials><ce:indexed-name>Stu G.</ce:indexed-name><ce:surname>Stu</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="1999"/><ref-volisspag><voliss volume="17"/><pagerange first="2700" last="2709"/></ref-volisspag></ref-info><ref-fulltext>Stuschke BM, Eberhardt W, Po C, Stamatis G, Wilke H, Stu G, et al. Prophylactic cranial irradiation in locally advanced Non Small Cell Lung Cancer after multimodality treatment: Long term follow up and investigation of late neuropsychological effects. J Clin Oncol 1999; 17: 2700-9.</ref-fulltext></reference><reference id="50"><ref-info><ref-title><ref-titletext>Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: A cochrane review</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">25844512692</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>J.F.</ce:initials><ce:indexed-name>Lester J.F.</ce:indexed-name><ce:surname>Lester</ce:surname></author><author seq="2"><ce:initials>F.R.</ce:initials><ce:indexed-name>Macbeth F.R.</ce:indexed-name><ce:surname>Macbeth</ce:surname></author><author seq="3"><ce:initials>B.</ce:initials><ce:indexed-name>Coles B.</ce:indexed-name><ce:surname>Coles</ce:surname></author></ref-authors><ref-sourcetitle>Int J Radiat Oncol Biol Phys</ref-sourcetitle><ref-publicationyear first="2005"/><ref-volisspag><voliss volume="63"/><pagerange first="690" last="694"/></ref-volisspag></ref-info><ref-fulltext>Lester JF, MacBeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: A Cochrane Review. Int J Radiat Oncol Biol Phys 2005; 63: 690-4.</ref-fulltext></reference><reference id="51"><ref-info><ref-title><ref-titletext>Cranial prophylactic irradiation in locally advanced non-small cell lung carcinoma: Current status and future perspectives</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">59749101889</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>E.</ce:initials><ce:indexed-name>Topkan E.</ce:indexed-name><ce:surname>Topkan</ce:surname></author><author seq="2"><ce:initials>B.A.</ce:initials><ce:indexed-name>Yildrim B.A.</ce:indexed-name><ce:surname>Yildrim</ce:surname></author><author seq="3"><ce:initials>U.Y.M.</ce:initials><ce:indexed-name>Selek U.Y.M.</ce:indexed-name><ce:surname>Selek</ce:surname></author></ref-authors><ref-sourcetitle>Oncology</ref-sourcetitle><ref-publicationyear first="2009"/><ref-volisspag><voliss volume="76"/><pagerange first="220" last="228"/></ref-volisspag></ref-info><ref-fulltext>Topkan E, Yildrim BA, Selek UYM. Cranial Prophylactic Irradiation in Locally Advanced Non-Small Cell Lung Carcinoma: Current Status and Future Perspectives. Oncology 2009; 76: 220-8.</ref-fulltext></reference><reference id="52"><ref-info><ref-title><ref-titletext>Prophylactic cranial irradiation in non-small cell lung cancer patients: Who might be the candidates?</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">80955124121</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>C.</ce:initials><ce:indexed-name>Dimitropoulos C.</ce:indexed-name><ce:surname>Dimitropoulos</ce:surname></author><author seq="2"><ce:initials>G.</ce:initials><ce:indexed-name>Hillas G.</ce:indexed-name><ce:surname>Hillas</ce:surname></author><author seq="3"><ce:initials>S.</ce:initials><ce:indexed-name>Nikolakopoulou S.</ce:indexed-name><ce:surname>Nikolakopoulou</ce:surname></author><author seq="4"><ce:initials>I.</ce:initials><ce:indexed-name>Kostara I.</ce:indexed-name><ce:surname>Kostara</ce:surname></author><author seq="5"><ce:initials>K.</ce:initials><ce:indexed-name>Sagris K.</ce:indexed-name><ce:surname>Sagris</ce:surname></author><author seq="6"><ce:initials>F.</ce:initials><ce:indexed-name>Vlastos F.</ce:indexed-name><ce:surname>Vlastos</ce:surname></author><et-al/></ref-authors><ref-sourcetitle>Cancer Manag Res</ref-sourcetitle><ref-publicationyear first="2011"/><ref-volisspag><voliss volume="3"/><pagerange first="287" last="294"/></ref-volisspag></ref-info><ref-fulltext>Dimitropoulos C, Hillas G, Nikolakopoulou S, Kostara I, Sagris K, Vlastos F, et al. Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates? Cancer Manag Res 2011; 3: 287-94.</ref-fulltext></reference><reference id="53"><ref-info><ref-title><ref-titletext>Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (proact)</ref-titletext></ref-title><refd-itemidlist><itemid idtype="SGR">84903740111</itemid></refd-itemidlist><ref-authors><author seq="1"><ce:initials>A.</ce:initials><ce:indexed-name>Tufman A.</ce:indexed-name><ce:surname>Tufman</ce:surname></author><author seq="2"><ce:initials>C.</ce:initials><ce:indexed-name>Belka C.</ce:indexed-name><ce:surname>Belka</ce:surname></author><author seq="3"><ce:initials>H.</ce:initials><ce:indexed-name>Kuenel H.</ce:indexed-name><ce:surname>Kuenel</ce:surname></author><author seq="4"><ce:initials>R.M.</ce:initials><ce:indexed-name>Huber R.M.</ce:indexed-name><ce:surname>Huber</ce:surname></author></ref-authors><ref-sourcetitle>J Clin Oncol</ref-sourcetitle><ref-publicationyear first="2012"/><ref-volisspag><voliss volume="30"/></ref-volisspag><ref-text>TPS7617</ref-text></ref-info><ref-fulltext>Tufman A, Belka C, Kuenel H, Huber RM. Prophylactic cranial irradiation after reaching complete response, partial response, or stable disease in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (ProACT). J Clin Oncol 2012; 30: TPS7617.</ref-fulltext></reference></bibliography></tail></bibrecord></item></abstracts-retrieval-response>